Life ScienceCompany
TenX BioPharma - Monoclonal Antibody Cancer Therapy Ownership
Who owns TenX BioPharma - Monoclonal Antibody Cancer Therapy?
TenX BioPharma - Monoclonal Antibody Cancer Therapy is owned by Emergent BioSolutions. It was acquired on June 6, 2011.
TenX BioPharma - Monoclonal Antibody Cancer Therapy Business Overview
Where is TenX BioPharma - Monoclonal Antibody Cancer Therapy headquartered?
TenX BioPharma - Monoclonal Antibody Cancer Therapy is headquartered in United States.
What sector is TenX BioPharma - Monoclonal Antibody Cancer Therapy in?
TenX BioPharma - Monoclonal Antibody Cancer Therapy is a life science company.
Life Science M&A Summary in 2011
Out of 60 sectors in the Mergr database, life science ranked 11 in number of deals in 2011. The largest life science acquisition in 2011 was Genzyme - which was acquired by Sanofi SA for $20.1B.
Join Mergr to view all 171 acquisitions of life science companies in 2011, including 23 acquisitions by private equity firms, and 148 by strategics.